Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Enterprise Value (2016 - 2025)

Perspective Therapeutics' Enterprise Value history spans 16 years, with the latest figure at -$321.5 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 3.97% year-over-year to -$321.5 million; the TTM value through Sep 2025 reached -$321.5 million, down 3.97%, while the annual FY2024 figure was -$226.9 million, 2356.33% down from the prior year.
  • Enterprise Value for Q3 2025 was -$321.5 million at Perspective Therapeutics, up from -$354.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$9.2 million in Q4 2023 and bottomed at -$379.0 million in Q1 2025.
  • The 5-year median for Enterprise Value is -$61.7 million (2021), against an average of -$137.9 million.
  • The largest annual shift saw Enterprise Value crashed 3079.9% in 2021 before it soared 78.89% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$60.4 million in 2021, then rose by 27.5% to -$43.8 million in 2022, then skyrocketed by 78.89% to -$9.2 million in 2023, then tumbled by 2356.33% to -$226.9 million in 2024, then plummeted by 41.67% to -$321.5 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Enterprise Value are -$321.5 million (Q3 2025), -$354.3 million (Q2 2025), and -$379.0 million (Q1 2025).